Cargando…

Self-therapeutic metal-based nanoparticles for treating inflammatory diseases

Inflammatory diseases are key contributors to high mortality globally and adversely affect the quality of life. Current treatments include corticosteroids or nonsteroidal anti-inflammatories that may cause systemic toxicity and biologics that may increase the risk of infection. Composite nanoparticl...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ruifang, Xiao, Yu, Bai, Qianqian, Choi, Chung Hang Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213990/
https://www.ncbi.nlm.nih.gov/pubmed/37250153
http://dx.doi.org/10.1016/j.apsb.2022.07.009
_version_ 1785047745535410176
author Han, Ruifang
Xiao, Yu
Bai, Qianqian
Choi, Chung Hang Jonathan
author_facet Han, Ruifang
Xiao, Yu
Bai, Qianqian
Choi, Chung Hang Jonathan
author_sort Han, Ruifang
collection PubMed
description Inflammatory diseases are key contributors to high mortality globally and adversely affect the quality of life. Current treatments include corticosteroids or nonsteroidal anti-inflammatories that may cause systemic toxicity and biologics that may increase the risk of infection. Composite nanoparticles that bear not only the drug payload but also targeting ligands for delivery to inflammation sites at lowered systemic toxicity are established in the nanomedicine field, but their relatively large size often leads to systemic clearance. Metal-based nanoparticles with intrinsic anti-inflammatory properties represent attractive alternatives. They are not only designed to be compact for crossing biological barriers (with the nanoparticle serving as a dual carrier and drug), but also support label-free tracking of their interactions with cells. The review commences with an outline of the common inflammatory diseases, inflammatory pathways involved, and conventional drug-loaded nanoparticles for anti-inflammation. Next, the review features the emerging applications of self-therapeutic metal-based nanoparticles (e.g., gold, coper oxide, platinum, ceria, and zinc oxide) for managing inflammatory diseases in animals over the past three years, focusing on therapeutic outcomes and anti-inflammatory mechanisms. The review concludes with an outlook on the biodistribution, long-term toxicity, and clinical translation of self-therapeutic metal-based nanoparticles.
format Online
Article
Text
id pubmed-10213990
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102139902023-05-27 Self-therapeutic metal-based nanoparticles for treating inflammatory diseases Han, Ruifang Xiao, Yu Bai, Qianqian Choi, Chung Hang Jonathan Acta Pharm Sin B Review Inflammatory diseases are key contributors to high mortality globally and adversely affect the quality of life. Current treatments include corticosteroids or nonsteroidal anti-inflammatories that may cause systemic toxicity and biologics that may increase the risk of infection. Composite nanoparticles that bear not only the drug payload but also targeting ligands for delivery to inflammation sites at lowered systemic toxicity are established in the nanomedicine field, but their relatively large size often leads to systemic clearance. Metal-based nanoparticles with intrinsic anti-inflammatory properties represent attractive alternatives. They are not only designed to be compact for crossing biological barriers (with the nanoparticle serving as a dual carrier and drug), but also support label-free tracking of their interactions with cells. The review commences with an outline of the common inflammatory diseases, inflammatory pathways involved, and conventional drug-loaded nanoparticles for anti-inflammation. Next, the review features the emerging applications of self-therapeutic metal-based nanoparticles (e.g., gold, coper oxide, platinum, ceria, and zinc oxide) for managing inflammatory diseases in animals over the past three years, focusing on therapeutic outcomes and anti-inflammatory mechanisms. The review concludes with an outlook on the biodistribution, long-term toxicity, and clinical translation of self-therapeutic metal-based nanoparticles. Elsevier 2023-05 2022-07-19 /pmc/articles/PMC10213990/ /pubmed/37250153 http://dx.doi.org/10.1016/j.apsb.2022.07.009 Text en © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Han, Ruifang
Xiao, Yu
Bai, Qianqian
Choi, Chung Hang Jonathan
Self-therapeutic metal-based nanoparticles for treating inflammatory diseases
title Self-therapeutic metal-based nanoparticles for treating inflammatory diseases
title_full Self-therapeutic metal-based nanoparticles for treating inflammatory diseases
title_fullStr Self-therapeutic metal-based nanoparticles for treating inflammatory diseases
title_full_unstemmed Self-therapeutic metal-based nanoparticles for treating inflammatory diseases
title_short Self-therapeutic metal-based nanoparticles for treating inflammatory diseases
title_sort self-therapeutic metal-based nanoparticles for treating inflammatory diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213990/
https://www.ncbi.nlm.nih.gov/pubmed/37250153
http://dx.doi.org/10.1016/j.apsb.2022.07.009
work_keys_str_mv AT hanruifang selftherapeuticmetalbasednanoparticlesfortreatinginflammatorydiseases
AT xiaoyu selftherapeuticmetalbasednanoparticlesfortreatinginflammatorydiseases
AT baiqianqian selftherapeuticmetalbasednanoparticlesfortreatinginflammatorydiseases
AT choichunghangjonathan selftherapeuticmetalbasednanoparticlesfortreatinginflammatorydiseases